merscov
merscov
cultur
vero
cell
grown
optimem
gibco
carlsbad
ca
fetal
clone
serum
hyclon
south
logan
ut
gentamicinkanamycin
gibco
viral
growth
assay
vero
cell
perform
previous
describ
gene
encod
indic
n
protein
synthes
bio
basic
ontario
canada
packag
venezuelan
equin
enceph
viru
replicon
particl
vrp
follow
vaccin
mous
polyclon
sera
gener
balbc
mice
neutral
assay
involv
merscov
strain
sarscov
describ
previous
western
blot
vrp
virusinfect
cell
lysat
control
prepar
describ
detail
blot
probe
use
indic
mous
polyclon
sera
vero
cell
inocul
merscov
isol
harvest
hour
infect
mean
trizol
reagent
invitrogen
use
perform
northern
blot
elisa
use
indic
virusinfect
cell
lysat
antigen
express
vrp
perform
describ
previous
reactiv
mous
human
serum
determin
use
chemiluminesc
substrat
block
elisa
perform
sequenti
react
platebound
merscov
lysat
antigen
convalescentphas
serum
obtain
patient
mer
follow
mous
polyclon
serum
rais
vrppackag
merscov
n
protein
block
express
percentag
reduct
reactiv
mous
serum
alon
merscov
mer
eng
isol
patient
sever
respiratori
ill
transfer
london
treatment
twentynin
mutat
mer
eng
amino
acid
level
identifi
compar
publish
sequenc
merscov
mer
sa
genbank
supplementari
figur
identifi
whether
mutat
alter
viru
growth
analyz
replic
kinet
isol
vero
cell
continu
epitheli
cell
line
figur
although
replic
kinet
slightli
differ
isol
vero
cell
peak
viral
titer
equival
contrast
viru
growth
markedli
distinct
human
cell
could
repres
differ
strainspecif
vitro
adapt
phenotyp
result
function
differ
sensit
innat
immun
respons
cov
replic
transcript
involv
product
nest
set
subgenom
messeng
rna
mrna
previou
report
predict
open
read
frame
mer
sa
mer
eng
northern
blot
analysi
identifi
subgenom
mrna
infect
virus
figur
observ
nest
set
subgenom
mrna
express
consist
observ
cov
open
read
frame
encod
mrna
isol
detail
supplementari
tabl
vrp
function
effici
express
vaccin
platform
varieti
antigen
gener
vrp
express
mer
sa
n
protein
immun
mice
n
antiserum
recogn
discret
band
predict
molecular
weight
lysat
vero
cell
supplementari
figur
cell
figur
infect
vrpn
differ
merscov
isol
part
similar
express
pattern
evid
vrp
virus
howev
n
protein
mer
eng
slightli
lower
molecular
weight
consist
amino
acid
delet
posit
supplementari
figur
mous
anti
serum
identifi
approxim
protein
vero
cell
supplementari
figur
observ
molecular
weight
consist
size
protein
cov
note
similar
result
cell
figur
interestingli
increas
amount
highermolecularweight
form
protein
glycosyl
dimer
note
mer
eng
cell
line
antiserum
mer
sa
n
protein
also
recogn
mer
eng
elisa
data
shown
n
protein
recogn
merscov
jordan
isol
supplementari
figur
plaqu
reduct
neutral
test
indic
complet
neutral
merscov
isol
titer
approxim
figur
merscov
jordan
isol
supplementari
vrp
antiserum
wherea
neutral
observ
n
antiserum
similar
find
report
sarscov
well
known
human
anim
cov
interestingli
serum
age
mice
vaccin
vrp
show
reduct
titer
approxim
indic
immunosenesc
attenu
vaccin
respons
merscov
antigen
note
sarscov
vaccin
use
serum
na
patient
elisa
demonstr
high
reactiv
patient
serum
n
antigen
mer
sa
express
vrp
figur
titer
antibodi
n
protein
patient
serum
peak
week
onset
ill
occur
septemb
wane
thereaft
antibodi
still
detect
month
ill
onset
titer
antibodi
protein
consist
week
week
ill
onset
remain
detect
importantli
patient
serum
collect
novemb
contain
high
titer
protein
outcompet
bind
mous
antiserum
intact
viru
block
assay
figur
data
suggest
differentoverlap
epitop
recogn
human
mous
antisera
follow
viru
vrp
infect
mer
sa
mer
eng
close
relat
btcov
hku
btcov
hku
figur
evalu
antigen
relationship
subgroup
betacoronavirus
vrp
express
n
protein
btcov
hku
btcov
hku
inocul
mice
antisera
hku
n
protein
recogn
n
protein
merscov
isol
wherea
mer
sa
n
antisera
also
detect
vrpexpress
hku
n
protein
reveal
western
blot
figur
obtain
similar
result
use
elisa
immunofluoresc
assay
data
shown
contrast
littl
observ
crossreact
observ
mer
sa
antisera
vrpexpress
protein
hku
hku
wherea
antisera
hku
protein
hku
protein
recogn
protein
merscov
isol
figur
also
measur
serolog
relationship
use
elisa
captur
crossreact
conform
epitop
confirm
antigen
relationship
figur
consist
result
serolog
test
antisera
hku
hku
protein
crossneutr
merscov
isol
data
indic
n
protein
glycoprotein
antigen
conserv
within
subgroup
betacoronavirus
evalu
panel
extend
analysi
highli
pathogen
sarscov
relat
subgroup
betacoronavirus
polyclon
mous
sera
sarscov
mer
sa
n
protein
exhibit
crossreact
reciproc
strain
figur
observ
low
level
crossneutr
mer
sa
mous
antisera
sarscov
use
high
low
concentr
serum
figur
find
consist
recent
report
interestingli
elisa
result
also
show
minim
crossreact
na
patient
sera
obtain
septemb
sarscov
antigen
figur
consist
observ
bind
mous
sarscov
antiserum
sarscov
inhibit
patient
sera
block
assay
figur
indic
absenc
antibodi
sarscov
patient
serum
conson
find
crossreact
observ
antisera
vrpexpress
n
glycoprotein
btcov
hku
merscov
isol
figur
furthermor
crossneutr
merscov
isol
hku
antiserum
observ
although
serum
previous
shown
neutral
synthet
resurrect
hku
variant
encod
sar
glycoprotein
receptor
bind
domain
interestingli
observ
low
level
crossneutr
sarscov
btcov
antiserum
figur
elucid
antigen
relationship
glycoprotein
alphacoronavirus
merscov
isol
express
gener
mous
antisera
btcov
btcov
hku
group
alphacoronavirus
use
vrp
platform
despit
effici
recombin
glycoprotein
express
figur
none
recombin
glycoprotein
recogn
mer
sa
antisera
antisera
hku
glycoprotein
littl
crossreact
neutral
merscov
figur
next
analyz
antigen
relationship
vrpderiv
mous
serum
follow
repres
hcov
subgroup
use
elisa
figur
mer
eng
subgroup
sarscov
subgroup
subgroup
subgroup
mer
eng
recogn
antisera
target
n
glycoprotein
virus
within
subgroup
betacoronavirus
likewis
sarscov
recogn
antisera
n
glycoprotein
virus
subgroup
betacoronavirus
none
antiserum
screen
react
subgroup
subgroup
although
btcov
hku
genet
close
observ
crossreact
within
glycoprotein
serum
patient
infect
sarscov
screen
n
protein
repres
subgroup
betacoronavirus
consist
previou
find
human
serum
sarscov
recogn
btcov
hku
btcov
sarscov
n
subgroup
recogn
n
protein
subgroup
figur
similarli
crossreact
human
antisera
subgroup
subgroup
infect
viral
antigen
within
panel
serum
collect
patient
infect
merscov
show
crossreact
bind
btcov
hku
n
subgroup
littl
crossreact
note
outsid
subgroup
figur
apart
low
transient
crossdetect
btcov
n
crossreact
sarscov
n
recombin
protein
singl
day
septemb
emerg
respiratori
cov
offer
consider
threat
health
global
popul
economi
platform
gener
wellcharacter
molecular
reagent
recombin
virus
need
detect
control
emerg
new
strain
especi
earli
outbreak
develop
typespecif
serolog
reagent
therapeut
character
genom
organ
subgenom
mrna
express
protein
express
pattern
isol
merscov
use
alphaviru
replicon
particl
synthet
gene
design
assembl
panel
recombin
protein
donor
antisera
phylogenet
distant
alphacoronavirus
betacoronavirus
evalu
antigen
relationship
strain
inform
vaccin
design
merscov
highli
pathogen
respiratori
cov
human
caus
acut
respiratori
distress
syndrom
mortal
rate
approach
cov
primer
set
success
diagnos
etiolog
jordan
outbreak
april
demonstr
critic
need
panel
reagent
set
recombin
protein
sera
allow
serolog
evalu
case
contact
case
asymptomat
infect
use
western
blot
elisabas
techniqu
articl
also
first
report
describ
serolog
character
merscov
cov
reagent
advantag
vrp
platform
also
function
vaccin
vector
afford
rapid
product
candid
vaccin
newli
emerg
strain
use
sarscov
merscov
model
clearli
demonstr
recombin
vaccin
elicit
robust
neutral
respons
young
age
rodent
model
vrp
vector
sarscov
protect
young
age
anim
develop
recombin
vector
vaccin
could
like
prove
success
prevent
heterolog
merscov
infect
age
individu
remain
test
mer
eng
replic
lower
titer
cell
virus
differ
passag
histori
vitro
tissu
cultur
adapt
mutat
may
account
differ
report
mani
sarscov
isol
altern
amino
acid
differ
describ
resid
replicas
polyprotein
supplementari
figur
may
affect
replic
effici
addit
glycoprotein
mer
eng
differ
mer
sa
amino
acid
supplementari
figur
may
account
increas
amount
highermolecularweight
form
protein
mer
eng
figur
supplementari
figur
recent
studi
indic
like
play
import
role
viral
entri
enhanc
fusogen
potenti
proteolyt
process
merscov
glycoprotein
addit
identifi
uniqu
mutat
mer
sa
isol
mer
eng
isol
show
mutat
respons
increas
vitro
fit
plaqu
morpholog
possibl
presenc
absenc
glycoprotein
mutat
mer
eng
may
result
slower
growth
phenotyp
cell
alphaviru
vrp
consider
potenti
recombin
viru
vaccin
platform
absenc
preexist
immun
demonstr
effici
express
sever
cov
n
structur
protein
vitro
vivo
result
robust
serolog
respons
vaccin
mice
antiserum
vrp
glycoprotein
vrpn
protein
neutral
isol
merscov
furthermor
other
demonstr
vaccineinduc
immunopatholog
observ
challeng
minim
vrp
vaccin
partli
thelper
type
immun
respons
high
neutral
titer
elicit
vrp
vector
importantli
vaccin
age
mice
demonstr
immunosenesc
contribut
reduct
magnitud
antibodi
respons
merscov
glycoprotein
import
point
consid
candid
vaccin
design
date
wildtyp
vrp
vrp
vaccin
repres
one
vaccin
platform
function
well
age
anim
addit
recombin
vaccin
poxvirusvector
vaccin
sarscov
pathogenesi
increas
agerel
suscept
link
increas
prostaglandin
express
remain
uncertain
whether
increas
prostaglandin
level
contribut
reduc
vaccin
perform
well
observ
merscov
replic
immunocompet
immunocompromis
mice
vector
must
test
directli
primat
safeti
vrp
platform
demonstr
highrisk
human
popul
immunosenesc
nonhuman
primat
believ
vector
efficaci
healthcar
worker
target
popul
infect
merscov
result
indic
presenc
strongli
crossreact
epitop
n
protein
within
particular
subgroup
subgroup
ident
condit
littl
crossreact
conserv
crossneutr
epitop
observ
protein
within
across
subgroup
similar
studi
show
strong
conserv
crossreact
epitop
n
protein
lesser
extent
protein
subgroup
cov
report
importantli
pattern
serolog
antigen
relationship
observ
use
mous
antisera
recapitul
use
human
antiserum
differ
cov
neutral
assay
demonstr
littl
conserv
crossneutr
epitop
glycoprotein
cov
within
across
subgroup
particular
absenc
crossneutr
merscov
isol
antiserum
hku
hku
glycoprotein
sarscov
antiserum
hku
btcov
glycoprotein
suggest
limit
conserv
possibl
deliber
mask
conserv
crossneutr
site
within
subgroup
although
specul
crossneutr
relationship
suggest
least
antigen
distinct
cov
could
emerg
zoonot
virus
circul
within
subgroup
reservoir
simultan
circul
human
find
evid
vaccin
design
new
emerg
cov
either
focu
develop
chimer
glycoprotein
contain
neutral
epitop
multipl
strain
within
across
subgroup
develop
new
paradigm
structureguid
antigen
design
improv
present
broadli
neutral
epitop
region
glycoprotein
interchang
cov
within
across
subgroup
render
viabl
recombin
virus
inclus
n
protein
chimer
vaccin
may
broaden
protect
respons
although
remain
test
use
lethal
challeng
virus
vaccin
might
provid
robust
protect
sever
homolog
heterolog
virus
within
across
genoclust
sarscov
epidem
stark
contrast
situat
emerg
influenza
virus
influenza
research
biomed
commun
fail
develop
broadli
applic
bioprepared
platform
rapid
respons
futur
emerg
cov
threat
cov
demonstr
acceler
pattern
zoonot
emerg
sinc
data
indic
appropri
diagnost
platform
includ
larg
panel
phylogenet
distinct
cov
n
structur
protein
must
valid
use
larger
panel
antisera
hcov
gener
popul
molecularbas
platform
like
polymeras
chain
reaction
deep
sequenc
offer
clear
advantag
earli
detect
activ
infect
public
health
respons
platform
would
strengthen
avail
recombin
protein
subgroup
typespecif
antisera
track
subclin
infect
determin
preval
infect
popul
identifi
hospitalacquir
infect
recent
report
identifi
subclin
case
merscov
infect
reversetranscript
polymeras
chain
reaction
screen
use
panel
recombin
protein
describ
would
provid
morespecif
inform
presenc
cov
case
vrp
platform
describ
yield
highlevel
express
key
recombin
protein
across
alphacoronavirus
betacoronavirus
also
provid
first
candid
vaccin
vector
potenti
augment
thelper
type
immun
respons
merscov
infect
reduc
associ
immun
patholog
vrp
approach
also
applic
improv
public
health
respons
control
futur
outbreak
highli
pathogen
emerg
infecti
diseas
due
cov
human
popul
